Literature DB >> 10207689

Medical treatment of prolactinomas.

M E Molitch1.   

Abstract

Prolactinomas are a common cause of reproductive and sexual dysfunction. Once other causes of hyperprolactinemia have been excluded with a careful history, physical examination, routine chemistries, and a TSH, MR imaging or computerized tomography will delineate the size and extent of the tumor. Medical therapy is the initial treatment of choice. When infertility is the primary indication for treatment, bromocriptine use has an extensive safety experience and is preferred. For other indications, however, cabergoline appears to be more efficacious and better tolerated. Transsphenoidal surgery remains an option, especially for patients with microadenomas, when medical therapy is ineffective.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207689     DOI: 10.1016/s0889-8529(05)70061-x

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  24 in total

1.  A non-functioning pituitary adenoma initially mimicking a microprolactinoma: The case for long-term follow-up of patients with mild hyperprolactinemia?

Authors:  M Losa; P Mortini; M Giovanelli
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

2.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 3.  Prolactinomas and pregnancy.

Authors:  Marcello Delano Bronstein
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 4.  Diagnosis and Management of pituitary disease with focus on the role of Magnetic Resonance Imaging.

Authors:  Amit Mahajan; Richard A Bronen; Ali Y Mian; Sacit Bulent Omay; Dennis D Spencer; Silvio E Inzucchi
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

5.  Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment.

Authors:  Pietro Scarone; Marco Losa; Pietro Mortini; Massimo Giovanelli
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 6.  Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature.

Authors:  Graciela Stalldecker; María Susana Mallea-Gil; Mirtha Guitelman; Analía Alfieri; María Carolina Ballarino; Laura Boero; Alberto Chervin; Karina Danilowicz; Sabrina Diez; Patricia Fainstein-Day; Natalia García-Basavilbaso; Mariela Glerean; Viviana Gollan; Débora Katz; Mónica Graciela Loto; Marcos Manavela; Amelia Susana Rogozinski; Marisa Servidio; Nicolás Marcelo Vitale
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

7.  Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases.

Authors:  P Cappabianca; S Lodrini; G Felisati; C Peca; R Cozzi; A Di Sarno; L M Cavallo; S Giombini; A Colao
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

Review 8.  Medical management of pituitary adenomas: the special case of management of the pregnant woman.

Authors:  Marcello Delano Bronstein; Luiz Roberto Salgado; Nina Rosa de Castro Musolino
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

9.  Pergolide as primary therapy for macroprolactinomas.

Authors:  J J Orrego; W F Chandler; A L Barkan
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

10.  Nonsurgical treatment of male infertility: specific and empiric therapy.

Authors:  Marcello Cocuzza; Ashok Agarwal
Journal:  Biologics       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.